Incyte Corporation is among the 11 Best Performing Biotech Stocks in 2025, making notable strides in oncology and autoimmune therapies. The company secured FDA approvals for Zynyz and Monjuvi, advanced its presence in myeloproliferative neoplasms, and is set to present promising assets at the ESMO Congress 2025.

Incyte Corporation’s KRAS cancer program is gaining attention with its innovative oral inhibitor designed to address G12D-mutated KRAS. The Phase 1 results expected at ESMO could provide the first clinical proof of concept, positioning Incyte as a pioneer in cancer drug development.

While Incyte shows investment potential, AI stocks may offer greater upside potential with less downside risk. For an undervalued AI stock that could benefit from current trends, consider exploring the best short-term AI stock mentioned in a free report.

For more insights on potential stock growth, check out the 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. No disclosures were provided in this article.

Read more at Yahoo Finance: Incyte Corporation (INCY) Advances KRAS Cancer Program